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Experimental autoimmune encephalomyelitisMultiple sclerosis (MS) is an inﬂammatory and demyelinating condition of the CNS, characterized by
perivascular inﬁltrates composed largely of T lymphocytes and macrophages. Although the precise cause
remains unknown, numerous avenues of research support the hypothesis that autoimmune mechanisms
play a major role in the development of the disease. Pathologically similar lesions to those seen in MS can be
induced in laboratory rodents by immunization with CNS-derived antigens. This form of disease induction,
broadly termed experimental autoimmune encephalomyelitis, is frequently the starting point in MS research
with respect to studying pathogenesis and creating novel treatments. Many different EAE models are
available, each mimicking a particular facet of MS. These models all have common ancestry, and have
developed from a single concept of immunization with self-antigen. We will discuss the major changes in
immunology research, which have shaped the EAE models we use today, and discuss how current animal
models of MS have resulted in successful treatments and more open questions for researchers to address.31 Mainz, Germany. Tel.: +49
ord), kurschus@uni-mainz.de
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The rodent model for multiple sclerosis (MS), experimental
autoimmune encephalomyelitis (EAE), has been extensively utilized
to unravel the mechanisms of autoimmune inﬂammation. Immuniza-
tion against myelin antigens will not exactly mimic the mechanisms
behind disease onset in humans, but when a putative treatment for
multiple sclerosis has been identiﬁed, efﬁcacy of this treatment in
different EAE models will often be a test of its relevance to the human
condition. Indeed, many therapeutics tested in multiple sclerosis
patients are in fact based on concepts derived from EAE data. In the
case of MS, we are dealing with a pathological state dependent on
immune cell trafﬁcking and cytokine production, which means that
there are numerous potential targets for treatment during disease
development. Firstly, attempts can be made to inhibit the initial
development of the pathogenic population. Secondly, the migration of
cells into the site of inﬂammation can be impaired. Finally, the effector
molecules produced by this population can be neutralized. In order to
identify a therapeutic target playing a role in any of these phases, or to
minimize side effects brought on by treatment with a particular
medication, the precise molecular mechanisms behind pathogenicity
must be uncovered. We will discuss some of the models utilized to
discover the mechanisms behind autoimmunity and in treatment
development, and their development.2. From rats to mice
Up until the 1980s, rats were the laboratory animals of choice
concerning the study of MS. Their popularity perhaps stemmed from
their being one of the ﬁrst models to be used as laboratory animals.
Perhaps it was the case that this model worked well. If compared to
mice, rats have the advantage of being large in size, and therefore easier
to work with their central nervous system (CNS), with relatively easy
methods to isolate and analyze spinal cord and brain. In addition, it is
much easier, compared with mice, to perform transplantation-based in
vivo experiments or intravital microscopy.
Of the different rat strains, the Lewis rats are themost popular in EAE
experiments. The disease in Lewis rats is very consistent and relatively
straightforward to induce. The lack of dependency on pertussis toxin to
achieve disease is also of beneﬁt, as this aspect of disease induction
more closely mimics the human situation. Rats immunized with myelin
basic protein (MBP) or one of the latter dominant peptides develop
disease in around 10 days, if the antigen is emulsiﬁed in complete
Freund's adjuvant (CFA) [1]. Another way of inducing EAE in rats is by
raising myelin-speciﬁc T cells by immunization of the rats with a
neuroantigen in CFA, followed by expansion and activation of the T cells
in culture. Once these T cells are activated, they will induce EAE when
transferred to naïve animals [2]. Manifestation of EAE in Lewis rats
consists of acute onset and spontaneous recovery, which resembles the
relapse of clinical signs seen in MS. However, demyelination in Lewis
rats is absent, and this is a hallmark feature of human MS. Furthermore,
inﬂammation in Lewis rats is predominantly localized in the spinal cord,
in stark contrast toMS. Thus, the ease of use of themodel has somewhat
precluded its suitability. Brown Norway and DA rats also show acute
inﬂammation after immunization with MOG-derived peptides, but also
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in rats is not a complete model for MS, but rather a robust model to
dissect the basic mechanisms involved in T cell-mediated
neuroinﬂammation.
For all the reasons mentioned above, rats remain a popular choice
as a model for MS. However, over the course of the 1980s, rats were
gradually superseded by mice. Mice are smaller and therefore
cheaper, allowing for more experiments and repetitions. As a result,
many modern reagents were generated for mice and not for rats. The
ﬂow cytometry revolution was accompanied by the generation of
monoclonal and polyclonal antibodies speciﬁc to mouse (and human)
cellular surface antigens. In comparison, fewer antibodies for ﬂow
cytometry were developed for rat antigens. The next big revolutions
in immunology, most notably the discovery of many new cytokines
and deﬁning their function, arrived at the time that mice were the
more popular laboratory animals. As a result, the focus shifted to
design of reagents for mice rather than rats. Collectively, it is today
more practical and productive to use mice as EAE models.
3. Gene-targeting as a driving force in EAE studies
Despite numerous practicalities in the usage of mice compared to
rats, the major reason for which mice remain the model of choice for
many EAE researchers lies in the generation of numerous immune-
deﬁcient mice, made possible and almost routine following the
pioneering work of Mario Capecchi, Martin J. Evans and Oliver
Smithies [5]. In the late 1980s, “gene targeting” was introduced to the
ﬁeld of immunology. This technique allowed for the inactivation of
genes and was rapidly seized upon to delete genes involved in
lymphocyte activation and cytokine signaling. By inactivating genes, it
is possible to efﬁciently determine if a protein is essential for a speciﬁc
mechanism. Obviously, this technology has become very popular in
many ﬁelds of biology far removed from immunology. Many proteins
now have deﬁned function, but their exact role in EAE is not always
obvious. In such cases, it makes sense to ablate the gene encoding
these proteins and induce EAE. In 1995, the group of Avraham Ben-
Nun published a paper that would shape the manner in which many
researchers investigate EAE [6]. In this report, EAE was induced in
mice with the H-2b allele of MHC II using a peptide of myelin
oligodendrocytes glycoprotein (MOG). Their discovery provided a
reliable method to induce the disease in C57BL/6 mice that until then
were not commonly used in EAE studies. Previously, a MOG-derived
peptide, MOG p35-55, had been shown to induce EAE in mice [7], but
the importance of the C57BL/6 strain to gene targeting made these
results of great importance. This encephalitogenic potential of the
MOG peptide p35-55 allowed inducing EAE in gene-targeted mice,
without time consuming and laborious backcrosses. Despite the fact
that BALB/c mice can also develop EAE when immunized in the
correct fashion [8], C57BL/6 mice still represent the model of choice
for many researchers given the relative ease of genomic modiﬁcation
and the increasing availability of immune-deﬁcient mice.
When gene targeting was established, most successful embryonic
stem (ES) cell lines were of 129 genetic background. In their
publication, Mendel et al. demonstrated that EAE could be induced
also in these mice when the MOG peptide is utilized. Therefore it was
obvious that mice of that genetic background were among the ﬁrst
used in EAE experiments of gene-targeted mice. One of the ﬁrst
knockout mice used were deﬁcient for the cytokine IL-6. IL-6 is a pro-
inﬂammatory cytokine secreted mainly by macrophages, and high
levels of it are found in the CNS of MS patients and EAE animals [9]. It
was not surprising therefore to ﬁnd that mice lacking IL-6 were
indeed completely resistant to EAE [10–12]. Resistance was associated
with the T cells, as it was found that IL-6 deﬁcient T cells are not
capable to induce the disease upon passive transfer [10]. Interestingly,
it was found that in mice deﬁcient for IL-6, Th1 or Th2 T cells cannot
develop, which was postulated to be the reason for the diseaseresistance [12]. It took a few more years until the discovery of
regulatory T cells, after which the group of Kuchroo solved the
problem with respect to IL-6 deﬁciency: they found that rather than a
direct role for IL-6 in the generation of encephalitogenic T cells, the
reason for the EAE resistance of these mice was the excessive
differentiation of regulatory T cells in the absence of IL-6, a potent
suppressor of Foxp3 [13]. After depletion of regulatory T cells, IL-6-
deﬁcient mice are again susceptible to EAE. Similar results could be
obtained in mice with deﬁciency in the IL-6 signaling pathway [14].
The original paper of the Ben-Nun group indicated that EAE
could be induced in H-2b mice using the MOG35-55 peptide [6]. At the
time, thiswas translated also to the usage of 129mice. However, it was
shown later that 129/Sv mice are resistant to EAE induction using
the MOG peptide. In fact, 129/Sv mice were only susceptible to MOG-
induced EAE when the IFNgR was genetically ablated on this back-
ground [15]. However, on a pure 129/Sv background, mice were
susceptible to EAE induction using MOG-peptide [16]. Unlike
the C57BL/6 strain, it is clear now that there are actually many
different 129 ‘sub-strains’, and some differ among each other as much
as C57BL/6 mice differ from BALB/c mice [17]. Given this uncertainty
surrounding the 129/Sv background, it was therefore clear that many
people continued to backcross the gene-targeted mice, for example to
C57BL/6. But in addition, new ES cell lines of the C57BL/6 origin were
developed, and they allowed the generation of gene-targeted mice
that are of pure C57BL/6 origin [18]. Although the methods used for
generation of new ES cell lines have progressed considerably in recent
years [19], still all commonly used ES cells lines are either of 129,
C57BL/6, BALB/c (which are resistant to EAE) or F1 genetic back-
ground. For that reason, the vast majority of mice are made with
C57BL/6 ES cells, and these can be directly used in EAE experiments.
Although C57BL/6 mice are now the choice of many EAE
researchers, disease induction is of a heterogeneous efﬁciency. From
our experience, disease is very much dependent on the Ptx used, and
on many unknown factors. Before C57BL/6 mice became so popular in
EAE studies, it was much more common to use SJL/J mice. In contrast
to C57BL/6 mice, disease induction is much more reliable. Another
important difference between SJL/J and C57BL/6mice is the possibility
to induce passive disease. It is possible to isolate T cell lines and clones
speciﬁc to the encephalitogenic antigen, when using SJL/J or C57BL/6.
But these T cell lines and clones are rarely encephalitogenic when
isolated from C57BL/6, while this is not the case for SJL/J T cells. The
only reliable manner to induce passive EAE in C57BL/6 mice is by
using relatively large number of activated and Th1-polarized MOG-
speciﬁc T cells.
4. Spontaneous EAE models
Unfortunately no natural animal mutant is known which develops
spontaneousMS-like symptoms in a similar fashion to theNODmouse,
which develops autoimmune diabetes. However, the establishment of
T cell receptor (TCR)-transgenic animals allowed for the analysis of
mice with a T cell repertoire heavily skewed towards speciﬁc
autoantigens. Theﬁrst TCR transgenicmouse directed against amyelin
antigenwas theMBP Ac1-10 speciﬁc line fromGoverman et al. in H-2u
(B10.PL)mice [20]. In contrast to other similarmouse lines [21,22] this
line developed an inconsistent spontaneous EAE in non-SPF mouse
facilities giving hints to non-deﬁned environmental triggers of disease.
In a clean facility the injection of pertussis toxin to transgenic animals
sufﬁced to induce EAE. Interestingly, under these conditions MBP-
speciﬁc antibodies were found, but their relevance was not further
investigated. Juan Lafaille backcrossed his line to the RAG-1 knockout
background and found 100% of spontaneous EAE [23]. His Lab also
found that transfer of WT CD4 T cells inhibited the spontaneous
development of EAE, which was a major milestone in the discovery of
CD4 Treg cells [24]. Thisﬁnding of a higher rate of spontaneous EAEwas
later reproduced by other groups using other TCR transgenic mouse
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speciﬁc TCR isolated fromMS patients, a humanMS predisposingMHC
class II allele and human CD4 [25]. Introducing the RAG2-knockout
background increased the spontaneous EAE in this model from 4% to
100%. Another very interesting spontaneous EAE model was the
creation of PLP139-151 speciﬁc TCR transgenic animals [26]. These mice
where backcrossed to either B10.S or SJL/J mice which are highly
susceptible to EAE. Interestingly two of the founder lines had such a
high incidence of spontaneous EAE when backcrossed to SJL/J, that
crossing was not possible beyond the ﬁfth generation. This led to the
ﬁnding that antigen presenting cells of SJL/J are readily activated, in
contrast to those from the congenic B10.Smice [27]. Amajormilestone
in EAE researchwas the creation of aMOG35-55-speciﬁc TCR transgenic
mice by Bettelli et al. [28]. These mice (termed 2D2) are now among
the most common TCR transgenic animals in EAE research. Although
these mice develop spontaneous EAE on WT (non-RAG) background
only at a low incidence between 4% and 15%, a larger proportion (more
than 30%) of these mice develop optical neuritis [28]. The creation of
these mice allowed for the ﬁnding of a new spontaneous EAE form,
namely opticospinal EAE (OSE). When crossed to B cell receptor
knockin Ig HMOG mice [29], the offspring developwith 50% incidence a
very consistent neuroinﬂammation conﬁned to the spinal cord and
optic nerve, reminiscent of Devic disease in humans [30,31]. Although
the lack of aquaporin-speciﬁc antibodies clearly hints at a distinct
etiology of both diseases, this model might give clues to site speciﬁc
inﬂammation found in different MS types. Since in this mouse, B cells
as well as T cells recognize the same antigen, this model, although
highly artiﬁcial due to combined transgenic TCR and BCR, may reveal
much about B-T cell cooperation during the induction of autoimmu-
nity. As indicated above, 2D2 mice develop spontaneous EAE at
somewhat different incidences, probably depending on the respective
animal facility. Since more than 90% of the T cells express the TCR
transgenic Vα and Vβ chains, which are speciﬁc forMOG35-55 and I-Ab,
it came as a big surprise that the spontaneous EAE was unaltered on
a MOG-deﬁcient background [32]. This was independently identiﬁed
in two different labs using two distinct MOG knockout strains [33,34].
A mixture of immunological and biochemical approaches led to the
ﬁnding that 2D2 T cells as well as a big proportion of primary
polyclonal MOG35–55-speciﬁc T cells (unpublished) do not only
recognize MOG35–55 but also a peptide of the axonal cytoskeletal
intermediary ﬁlamentous protein Neuroﬁlament-M (NFM18–30).
When both MOG and NFM were knocked out simultaneously in
recipient animals, 2D2 T cells were unable to transfer disease [32].
The discovery that a single T cell can possess speciﬁcity to multiple
autoantigens of the same target organmayhavemajor implications for
the understanding of the development of autoimmunity in general.
Most spontaneous EAEmodels, including the upper ones described
using 2D2 animals, develop acute/chronic forms of EAE. Therefore, the
establishment of a MOG-speciﬁc TCR-transgenic mouse line develop-
ing spontaneous relapsing remitting (RR)-EAE was of major impor-
tance [35]. In many cases MS develops as a relapsing-remitting form
and therefore, mechanisms governing these processes of disease
conﬁnement and resurrection are of relevance to MS research. In “RR-
mice” nearly all CD4 T cells are speciﬁc for MOG92-106, which is the
dominant encephalitgenic MOG epitope in the H-2s background [7].
Interestingly this mouse not only spontaneously developed a high
frequency of spontaneous RR-EAE, but it was also found that B cells
from the endogenous repertoire were recruited to produce high
amounts ofMOG speciﬁc antibodies. The early depletion of B cells with
anti-CD20 treatment was inhibiting disease onset and sera of TCR
transgenic mice where shown to activate complement and to be pro-
pathogenic [35]. Thismodel therefore is highly relevant for the study of
pattern II MS where complement deposition and T cells are found in
lesions [36,37]. It is also an important model especially since depletion
of B cells and plasmapheresis is highly efﬁcient in a subgroup of
treatment resistant patients [38]. The most TCR transgenic models arebased onCD4 T cells recognizingmyelin peptides bound toMHCclass II
alleles. Three different MHC class I-speciﬁc CD8 EAE models are
published, two of which also develop spontaneous EAE [39–41]. The
ﬁrst is an adaptation of the antigen to the existing OTI ovalbumin
speciﬁc mouse line, where ovalbumin was expressed in the cytosol of
ODCs under the control of theMBP promotor. F1 offspring developed a
very drastic form of neuroinﬂammation at a very early age of 2 weeks
[40]. Using this and similar models, direct killing processes in the CNS
can be investigated and visualized [42,43]. Although generation of a
CD8 model for MS is in demand, the very early disease onset and the
artiﬁcial autoantigenof thismodelwill not end thehunt for a betterMS
like CD8 model. A recently published report used human TCR
transgenic mice derived from a CD8 cell clone recognizing PLP45-53
bound to the humanMHC class I alleleHLA-A3 [41]. In thismodel, 4% of
double transgenic animals on theHLA-A3backgrounddevelopedweak
spontaneous motor deﬁcits, demonstrating that HLA-A3 is pro-
pathogenic whereas coexpression of HLA-A2 was inhibiting disease,
either induced or spontaneous, via early thymic selection pressure on
TCR transgenic T cells. Interestingly, Mars and colleagues were able to
show that naïve CD8 T cells tolerate oligodendrocytes expressing a
neo-self antigen, in this case an inﬂuenza hemagluttinin (HA)
expressed in these cells using a transgenic approach. When effector
CD8 T cells bearing the transgenic TCR speciﬁc for HAwere transferred
into these host mice, demyelination and inﬂammation were observed
in the CNS [44]. Thus, despite the accumulation of CD8 T cells in MS
lesions [45], these results still point to a peripheral activation of CD8 T
cells and oligoclonal expansion of these experienced T cells in the CNS.
There are more spontaneous EAEmodels published than described
here, but common to all is that they are based on TCR transgenic
animals. It seems that at least in mice a relatively high number of
myelin speciﬁc T cells are a pre-requisite for spontaneous EAE
development. Although spontaneous EAE models bear the inherent
disadvantage of a heterogeneous disease onset time and varying
incidences, their development by transgenesis has resulted in many
unexpected and interesting discoveries.
5. Development of MS treatments using murine models
Oftentimes it is through failures that the ﬁeld of MS research has
moved forward. It is also the case that therapies that show incredible
promise in animal models will not translate to a successful therapy.
For example, antibodies directed to deplete T cells showed no
signiﬁcant beneﬁcial effect in the clinic [46]. However, as in the case
of the monoclonal antibody TGN-1412 designed to activate Tregs in a
CD28-dependent manner, multiple organ failure can be the conse-
quence [47]. It is thus with an air of caution that we should translate
our ﬁndings in rodent models to the human system. Despite a number
of setbacks, we are fortunately able to discuss a number of successful
therapies developed in animal models.
It is unusual that the use of IFN-β to treat MS patients has been a
highly successful therapy for 15 years, but we still lack the knowledge
as to the mechanisms behind the therapeutic beneﬁts of IFN-β
treatment. Therefore, understanding the reasons behind this effect
can be of central importance to gaining a deeper understanding of at
least some the molecular mechanisms involved in MS pathogenesis.
Type 1 interferons such as IFN-β are produced by most cell types in
response to virus, bacteria or cellular components thereof. They are in
essence proinﬂammatory cytokines that stimulate the immune
response on a number of levels.
Type-I IFN signaling has been shown to induce production of
cytokines and chemokines, induce maturation of dendritic cells and
induce immunoglobulin class-switching in B cells [48]. Differing
outcomes have been reported with respect to the efﬁcacy of IFN-β in
controlling EAE, anddifferent studies have reported variable efﬁcacy of
IFN-β depending on the animal model used and method of EAE
induction or IFN-β treatment. While some reports have shown a clear
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51], other investigators have reported that IFN-β has no effect on
disease progression [52], or even can lead to exacerbation of the
disease [53]. Nevertheless, there is no doubt that the therapeutic
properties of IFN-β are related to its impact on the activity of T
lymphocytes as deduced from the fact that in vitro treatment of
encephalitogenic T cellswith IFN-β renders them insufﬁcient to induce
passive EAE [54,55]. However, important results from Prinz et al.
described how antigen-restimulated T lymphocytes from wild type
mice induced a signiﬁcantly stronger clinical disease state in type I IFN
receptor (IFNAR)-deﬁcient mice, indicating that IFNAR expression on
host-derived cells is of importance during disease induction [56].
Other recent studies have in fact shown that IFN-β treatment reduces
the number of Th17 cells in activeMS,while not altering the number of
Th1 cells in circulation [57].
On the contrary, IFN-α has been shown to be proinﬂammatory in
the CNS, after mice which overexpress IFN-α in the CNS were shown
to suffer from inﬂammation and subsequent neurodegeneration [58].
However, reports have emerged which outline an anti-inﬂammatory
role for IFN-α in disease pathogenesis. Systemic administration of
IFN-α resulted in a reduced mortality in response to endotoxic shock
in LPS-challenged mice [59]. This ﬁnding was transferable to the ﬁeld
of EAE research, where delivery of IFN-α inhibited actively induced
EAE [60]. More recently, and with the advent of genetically modiﬁed
mice discussed previously, both IFN-β and IFN-γ-deﬁcient animals
were shown to be hyper-susceptible to EAE pathogenesis [15,61,62].
Mice deﬁcient in Type 1 IFN receptor also develop a more aggressive
experimentally induced colitis [63]. Taken together, enough evidence
has been collected to describe a profound anti-inﬂammatory effect of
type 1 interferon, but only under certain conditions. The discrepancy
between pro- and anti-inﬂammatory effects of Type I IFN remains,
for now, incompletely understood.
The basis of our understanding of the cell types and molecular
effectors mediating the pathogenesis of EAE has escalated dramati-
cally. However, it is important to question some basic principles on
which current EAE research has been founded. For example, the
observation that myelin-speciﬁc Th1 cells were sufﬁcient to induce
EAE in mice directed the ﬁeld of MS research toward IFN-γ, the
hallmark cytokine of these pathogenic effector cells. It was clearly
demonstrated however that both healthy individuals and MS patients
harbor myelin-speciﬁc CD4+ T cells, but these cells are more likely to
have a Th1 phenotype in MS patients [64]. It was therefore surprising
that numerous reports illustrate a protective effect of IFN-γ with
respect to EAE pathogenesis. Both IFN-γ-deﬁcient mice and mice
treated with neutralizing antibodies designed to inhibit IFN-γ
signaling were still susceptible, or even hyper susceptible to EAE
[65,66]. IFN-γ enhances antigen presentation via MHC upregulation
and also positively regulates Th1 differentiation. On the other hand, a
pathogenic role for IFN-γ is supported by genetically manipulated
mice, which lack suppressor of cytokine signalling-1 (SOCS1), a
negative regulator of IFN-γ [67–69]. A complex and lethal disease
initiated by the absence of SOCS1 was prevented using neutralizing
anti-IFN-γ antibodies, or when the SOCS1 deﬁciency was crossed to
the IFN-γ-deﬁcient background. Despite many efforts to uncover the
mechanism behind a protective role for IFN-γ, answers have
remained elusive. It was recently shown that IFN-γ signaling down-
regulates expression of IL-1R on macrophages [70]. Chen Dong and
colleagues were able to describe a crucial role for the IL-1β/IL-1R axis
in the development of EAE and early generation of Th17 cells. IL-1
receptor expression in T cells, which was shown to be upregulated
after IL-6 signaling, was required for the induction of EAE and Th17
cell differentiation in vivo [71]. IL-1β was shown to regulate the
expression of the transcription factors RORγt and IRF4 during Th17
cell differentiation, placing IL-1β signaling as an early event in Th17
differentiation. Overexpression of either transcription factor resulted
in Th17 cytokine expression independently of IL-1β. Thus, IFN-γmaydownregulate IL-1R expression on immune cell types and ultimately
diminishes their potential to mount an inﬂammatory response.
Nearly two decades ago, studies of molecules involved in
lymphocyte interaction with inﬂamed epithelium revealed a critical
role for the α4 integrin [72]. Neutralizing antibodies directed against
the α4-integrin subunit were clearly shown to reduce the severity of
EAE, highlighting the importance of T cell migration into the CNS for
the progression of disease [73]. Indeed, understanding thismechanism
led to the development of Natalizumab, which proved to be beneﬁcial
in reducing inﬁltrates into the cerebrospinal ﬂuid of MS-patients
[74]. The development of Nataluzimab as an effective MS treatment
constitutes the bona ﬁde example of a hypothesis driven discovery of a
drug, found and developed with the help of the EAE model. However,
murinemodels can also be used retrospectively, as is currently the case
with glatiramer acetate, the generic term used for Copaxone. After a
sustained period of successful therapy using this substance, research-
ers are still using actively induced EAE to uncover the mechanisms
behind the beneﬁcial actions of this treatment [75–78].
6. Th17 cells in EAE and MS
With respect to Th17 cells in EAE, much focus has been placed on
unraveling the transcription factors and cytokine requirements for their
development [13,79], and more recently, effector maintenance [71,80].
Given the already pre-existing link between MS lesions and IL-17
production [81], the immunological community believed that a major
breakthrough in MS treatment was on the horizon after the discovery
that IL-17A-expressing T cellswere highly efﬁcient in inducing EAE [82].
While the pathogenic role of Th17 cells has been described in a number
of disease models (CIA, EAE, EAU) [83–85], the molecular explanation
behind the pathogenicity of Th17 cells is now undoubtedly more
complex than this single hallmark cytokine. For example, adoptively
transferred Th17 cells failed to induce EAE in C57BL/6mice [86]. IL-17A-
deﬁcient or anti-IL-17A-treated mice are indeed able to develop EAE,
though the kinetic and severity of disease is reduced, albeit to varying
degrees [87–89]. When one contrasts this milder phenotype with the
absolute and reproducible resistance of IL-23p19-deﬁcient or IL-6R
deﬁcient mice [14,84], it is clear that IL-23 and IL-6 signaling on T cells
results in more than just Th17 development. Indeed, TGF-β and IL-6-
polarized Th17 cells per se are not able to induce EAE, even if they are
myelin-speciﬁc [90]. In contrast IL-23-driven myelin-speciﬁc Th17 cells
were able to induce EAE [91]. However, the results from a clinical trial
using anti-p40 to treatMSpatientswasunsuccessful, showing that IL-23
in humansmay indeed not be themajor player in the human condition,
and as suchhighlight possible differences in themolecular requirements
for EAE andMS pathogenesis. The clinical trial was, however, conducted
on patients with wide ranging MS pathogenesis, and in part after years
of suffering with MS. As IL-23 has been shown to be essential in
induction of EAE, it was conversely shown to be dispensable for
maintenance of disease [92]. Thus, IL-12/23 p40 treatmentmay function
better when administered much earlier in the disease development. IL-
17-producing CD4+ and CD8+ T-cells are nonetheless detectable in
active and chronic MS, and consist of both CD4 and CD8 T-cells [93].
Thus, elucidating a role for Th17 cells in MS is indeed a worthwhile
endeavor, but accumulating evidence from both EAE and clinical trials
suggests that the causes ofMS aremore complex. Onemust not rule out
the current theory that Th17 cells are highly ﬂexible in their cytokine
repertoire [94], and although IL-17A expression is indeed linked to Th17
cells, the Th17' phenotype may only represent a stage in the life of an
effector cell, and subsequently expressed cytokines are the true
pathogenic molecules.
7. Concluding remarks
All current evidence identiﬁes MS as a complex disorder, and as
such is safe to conclude at this point that no single animal model of
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in the human condition. MS and EAE are in essence different disease
states, and much evidence suggests that the EAE models do not
accurately reﬂect the pathology of a progressive condition, which is
the nature of MS. The numerousmodels of EAE are at best dissimilar in
their pathology and immunology, which hampers our certainty of
which EAE model will be more suitable. The mice used in EAE
experiments are generally inbred, so genetic differences are essentially
excluded from analyses and do not reﬂect what one might encounter
in the human population.
On a more positive note however, diversity within the ﬁeld of EAE
has its advantages. Each model may accurately mimic one particular
facet of MS. Gene targeting advances in mice allow us to pinpoint
molecules of interest with incredible precision, and as such can greatly
accelerate the process of identifying proinﬂammatory mediators and
mechanisms behind the inﬂammation observed in EAE models.
Although the commonly used EAE model was criticized for its
limitation in the development of MS treatments [95], it has also
brought great success in the form of Copaxone and Natalizumab.
Another major advantage of EAE models is speed. New results
generated in EAE provide rapid indications of whether a particular
treatment regimen might be of use when transferred to the human
system. Taken together, we must conclude that despite numerous
drawbacks, EAE has been an extremely valuablemodel in investigating
the pathogenesis and developing new medications to help those
suffering from multiple sclerosis.
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